Algorand Foundation Announces Research Leadership
The Algorand Foundation today announced the appointment of Dr. Tal Rabin as the head of research. Named on Forbes World Top 50 Women in Tech 2018 and a member of the National Academy of Arts and Sciences, Dr. Tal Rabin has spent decades pioneering research on cryptographic theory. Dr. Rabin will bring her wealth of experience, specifically around multiparty computations and the design of efficient and provably secure cryptographic protocols, to her work at the foundation.
With core beliefs in the establishment of an open, public and permissionless blockchain, the Algorand Foundation has a vision for an inclusive ecosystem that provides an opportunity for everyone to harness the potential of an equitable and truly borderless economy. With the appointment of Dr. Tal Rabin as the head of research, the foundation is poised to make that vision a reality with broad participation and a focus on cutting-edge research and innovation.
A first-of-its-kind permissionless, pure proof-of-stake blockchain, the Algorand protocol was designed by MIT professor, cryptography pioneer and Turing Award-winner Silvio Micali to support the scale, open participation, and transaction finality needed by users to build opportunity and fulfill the promise of blockchain technology. The Algorand Foundation directs its global efforts from Singapore and is focused on building technology and community around decentralized networks. The foundation, along with the Algorand community, will help launch the Algorand blockchain network while also assisting with research efforts, collaborative roadmap development, and continued growth of the global community.
“Given Dr. Rabin’s experience and academic accomplishments, the Algorand Foundation will be able to take a leadership role in research related to fair access, social justice for all, as well as zero knowledge and secure computation,” said Silvio Micali, founder of Algorand, Inc. “Tal brings tremendous energy to these issues, and I have always admired her passion for philanthropic efforts enabled by technology and innovation, particularly when it comes to her unwavering commitment to gender equality. I am thrilled she has agreed to join the Algorand community.”
“I’ve always believed in the concept of making our world a fairer place, and I trust the Algorand blockchain can create the economic opportunity needed to make that world a reality,” said Rabin. “Our work at the Algorand Foundation will ensure that equitable access to opportunity through decentralized technologies exists, transactions flow freely and everyone has control over their data. I’m excited to start working toward that goal with the accomplished team at the Algorand Foundation.”
In the coming weeks, the Algorand Foundation will share more details about the public network, including the distribution of Algos – the official native token of the Algorand protocol – as well as information about grants for research and development, growth, and economic guidance.
About Algorand Foundation
The Algorand Foundation is providing the trusted infrastructure needed to support the growth of the borderless economy. With research led by Dr. Tal Rabin, a 2018 Forbes World Top 50 Women in Tech, the Algorand Foundation is incorporated in the Republic of Singapore.
For more information, visit https://algorand.foundation.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
GLIDE and eBay Present the 20th Annual Auction for Power Lunch with Warren Buffett, May 26 – May 3120.5.2019 11:00:00 CEST | Pressemelding
GLIDE is pleased to announce the annual eBay for Charity Auction for Power Lunch with Warren Buffett, which will begin at 7:30 pm PDT on Sunday, May 26 and end at 7:30 pm PDT on Friday, May 31, 2019. This year marks the 20th anniversary of the legendary auction, which to date has provided nearly $30 million to support GLIDE’s comprehensive suite of social services that help San Francisco’s most vulnerable residents overcome hunger, poverty, homelessness and health challenges as well as social isolation and marginalization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005017/en/ “It makes a difference, and it translates into human beings finding that there is hope in life and that something better is there,” Mr. Buffett said recently about the money raised for GLIDE over the past 20 years. The annual Power Lunch with Warren Buffett is made possible through the support of eBay for Charity. The winning bidder and up to
PEI-Genesis Promotes Peter Austin to General Manager North America and Corporate Senior Vice President20.5.2019 11:00:00 CEST | Pressemelding
PEI-Genesis, the world’s fastest assembler of precision connectors, has promoted Peter Austin to General Manager North America and Corporate Senior Vice President, effective immediately. He will continue to report directly to Steven Fisher, PEI-Genesis Chairman and CEO. “Since joining PEI-Genesis in 2016, Peter has proven to be a valuable leader and an unparalleled strategic thinker in working to move the business forward,” said Fisher. “With his decades of experience in the electronics industry, his innovative thinking, and his ability to lead teams across North America, we have many accomplishments to tout, all directly related to his work.” In addition to his current responsibilities, in his new General Manager role, Austin will have responsibility for all operations in North America, including the company’s production facilities in South Bend, IN, Chandler, AZ, and Nogales, Mexico. He’ll also have leadership of the company’s North American Sales units. “My tenure at PEI has been a
Enlighted Expands IoT Platform Lighting Control Capabilities20.5.2019 10:00:00 CEST | Pressemelding
Enlighted, the leading provider of Internet of Things (IoT) solutions for commercial buildings and healthcare facilities, today announced new lighting control capabilities have been added to its award-winning building IoT Platform. These include advanced tunable white lighting control, daylight harvesting group capabilities, and a two-wire interface for the company’s powerful sensors. Together these new advancements improve the health and well-being of building occupants, improve lighting aesthetics, simplify fixture integration and reduce costs. Advanced Tunable White Lighting Control Enlighted sensors go beyond the automated circadian rhythm capabilities typically found in today’s tunable white solutions and now provide user-level control of color temperature to desired levels. The color temperature can be automatically aligned with the astronomical clock or directly tuned according to specific user needs. Occupants can tailor their environment, improve productivity and comfort, and
ams, Ibeo and ZF Partner to Deliver Industry-First Solid-State LiDAR Systems for the Automotive Industry20.5.2019 09:36:00 CEST | Pressemelding
ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, announces today that it has signed an agreement to team with Ibeo Automotive Systems GmbH, the German specialist for automotive LiDAR sensor technology, and ZF Friedrichshafen AG, one of the leading technology companies for mobility worldwide to advance solid-state LiDAR technology for use in autonomous driving and other applications. The three companies will partner on joint R&D efforts to ensure that this exciting technology can be quickly and safely adopted by 2021. LiDAR is an optical sensing technology that measures distance and direction of the surrounding objects by illuminating them with a laser beam and detecting the reflection of the object. Its unique range and resolution properties complement radar and camera solutions to enable the ‘Holy Grail’ of the self-driving car industry – SAE level 5* or fully autonomous driving. ams will provide automotive-grade VCSEL (Vertical Cavity Surface Emittin
Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 201920.5.2019 07:05:00 CEST | Pressemelding
Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21st at 11:00 AM BST. The presentation, entitled “Advancing Precision Oncology Biomarker Discovery with a Multi-dimensional Immunogenomics Platform,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT™. In addition to an overview, the presentation will introduce preliminary data from an ongoing study in which this platform is being used to evaluate IO-related biomarkers and potential tumor escape mechanisms in a cohort of melanoma patients treated with anti-PD-1 therapy. ImmunoID NeXT™ is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one. This maximizes the
New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery20.5.2019 07:00:00 CEST | Pressemelding
Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005244/en/ Masimo Radical-7® with SpHb® (Photo: Business Wire) Noting that because of the “invasive, time-consuming and intermittent” nature of invasive blood sampling, clincians often forgo these “objective indications” when making transfusion decisions during surgery, Dr. Tang and colleagues sought to determine whether noninvasive, continuous hemoglobin monitoring could aid clinicians in estimating when it might be appropriate to perform an invasive measurement. They enroll